We are a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease. Our team is committed to adhering to scientific excellence and dedicated to serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet need.
Treatment Pipeline
View Pipeline
Revumenib
Beyond its initial indication, Syndax is also investigating revumenib in other genetically defined acute leukemias such as those with an NPM1 mutation, where a pivotal trial is ongoing.
Explore MoreAxatilimab
In addition to its first indication, Syndax aims to investigate axatilimab in earlier lines of therapy in combination with standard of care agents and in potential indications such as idiopathic pulmonary fibrosis, where a Phase 2 clinical trial is ongoing.
Explore more
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update
Syndax is proud to announce a major milestone that the U.S. Food and Drug Administration has approved Revuforj® (revumenib)!
Read Our Press ReleasePlease see Full Prescribing Information, including BOXED WARNING here.